Buy Barigen baricitinib at a competitive price in India
Barigen 4 mg is a prescription tablet containing baricitinib, an inhibitor of Janus kinases JAK1 and JAK2. This listing is for a 30-tablet pack labelled General Pharmaceuticals Ltd. Treatment must be selected by a clinician who knows the diagnosis, previous medicines, blood-test results and the patient's medical history.
The U-HIV price is USD 38 per pack, with a minimum order of 4 packs. Shipping from India costs USD 30. Four packs cost USD 152, making the stated minimum order total USD 182 including shipping. General Pharmaceuticals Ltd. is based in Bangladesh; shipping from India describes the dispatch route and should not be confused with the manufacturing country.
Understanding the active ingredient
JAK enzymes transmit signals from cytokines involved in inflammation and immune responses. By inhibiting selected enzymes in this pathway, baricitinib can modify inflammatory activity in conditions for which it has been prescribed. It is not an antibiotic, a routine hair supplement or an occasional painkiller. The benefit expected from treatment and the appropriate review date depend on the disease being treated.
Uses and the role of a specialist
European information for the reference medicine Olumiant includes rheumatoid arthritis, severe alopecia areata, atopic dermatitis and certain forms of juvenile idiopathic arthritis. Eligibility and age limits are indication-specific. These are facts about baricitinib and the reference product; they do not establish that every indication is authorized for the Barigen brand in every country.
A rheumatologist may assess response to earlier disease-modifying treatment before considering a JAK inhibitor. A dermatologist must identify the cause of hair loss before treating alopecia areata, since other forms of hair loss require different care. The 4 mg strength on this pack is not a universal daily dose. Kidney function, other medicines and individual risk can change the treatment selected by the prescriber.
Checks before treatment
- Confirm the diagnosis, intended strength and compatibility with the existing prescription.
- Discuss tuberculosis and viral hepatitis screening, blood counts, kidney function and liver tests.
- Tell the clinician about blood clots, cardiovascular disease, cancer history and recurring infections.
- Agree on vaccination planning, follow-up tests and a schedule for assessing response.
Contraindications and safety considerations
The European product information contraindicates baricitinib in pregnancy and in patients allergic to the active substance or relevant excipients. Breastfeeding requires a specific discussion with the prescriber. Active tuberculosis or a serious infection must be assessed before treatment starts. Abnormal blood counts or impaired kidney function may require treatment modification or make treatment unsuitable.
Important risks include serious infections, thrombosis, major cardiovascular events and malignancy. Lipids and other laboratory measurements can change during treatment. Fever, a painful rash, sudden breathlessness, chest pain or swelling of one leg require prompt medical attention. Other JAK inhibitors, biologic immune therapies or strong immunosuppressants should never be added without specialist advice.
Ordering a 30-tablet pack
- Match the prescription to Barigen, baricitinib 4 mg and the 30-tablet pack.
- Select at least four packs and provide the delivery destination.
- Confirm availability, batch expiry and dispatch timing with the order manager.
- Check the seal and labelling on arrival and keep the manufacturer's leaflet.
Storage must follow the instructions printed on the supplied pack, which should be kept away from children. The listing image is a prepared packaging illustration; the label on the actual batch may differ. This product overview supports accurate ordering and does not replace the Barigen leaflet or individualized medical instructions.